Product image of Opdivo (Nivolumab) supplied by GNH India

Opdivo

Active Ingredient:
Nivolumab
Origin:
EU

Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a PD‑1 inhibitor presented as a sterile solution for subcutaneous use. It is employed in cancer immunotherapy to enhance the immune system’s ability to target tumor cells in adult patients with specific malignancies.

GNH India supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bristol-Myers Squibb Pharma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Opdivo acts on the programmed death‑1 pathway and is indicated for several advanced cancers.

  • Melanoma: improves overall survival in patients with unresectable or metastatic disease.
  • Non‑small cell lung cancer: used as first‑line or subsequent therapy for advanced disease.
  • Renal cell carcinoma: extends progression‑free survival in metastatic cases.
  • Classical Hodgkin lymphoma: provides durable responses in relapsed or refractory patients.
  • Head and neck squamous cell carcinoma: enhances response rates when combined with chemotherapy.
  • Urothelial carcinoma: offers treatment option for locally advanced or metastatic disease.

How It Works

  • Nivolumab is a fully human IgG4 monoclonal antibody that binds to the programmed death‑1 (PD‑1) receptor on activated T cells. By blocking the interaction between PD‑1 and its ligands PD‑L1/PD‑L2, the drug prevents the inhibitory signaling that dampens T‑cell activity, thereby restoring and amplifying a tumor‑specific immune response that can lead to cancer cell elimination.

Side Effects

Adverse reactions to Opdivo can range from mild to severe and are related to immune system activation.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Rash: skin eruptions that may be itchy or painful.
  • Pruritus: generalized itching without visible rash.
  • Diarrhea: loose stools that may lead to dehydration.
  • Nausea: sensation of unease and urge to vomit.
  • Infusion‑related reactions: flushing, chills, or fever during administration.

Serious or Rare Side Effects

  • Pneumonitis: inflammation of lung tissue that can impair breathing.
  • Colitis: severe inflammation of the colon causing abdominal pain and diarrhea.
  • Hepatitis: liver inflammation leading to elevated enzymes.
  • Endocrinopathies: dysfunction of thyroid, pituitary, or adrenal glands.
  • Nephritis: kidney inflammation potentially reducing renal function.
  • Severe infusion reactions: anaphylaxis or hypotension requiring emergency care.

Precautions & Warnings

Before initiating Opdivo, clinicians should consider several safety measures.

  • Monitor for immune‑related adverse events: watch for signs of organ inflammation such as cough, diarrhea, or jaundice.
  • Assess baseline organ function: perform liver, kidney, and thyroid tests prior to treatment.
  • Avoid use in patients with active uncontrolled infections: postpone therapy until infection is resolved.
  • Consider vaccination status: live vaccines are contraindicated during treatment.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Opdivo may interact with other therapies that influence immune function.

Major Interactions (Avoid)

  • Concurrent high‑dose systemic steroids: may diminish therapeutic efficacy.
  • Organ transplantation: increased risk of graft rejection due to immune activation.
  • Other immune checkpoint inhibitors: combined use can amplify toxicity.
  • Live vaccines: can cause uncontrolled infection.

Moderate Interactions (Monitor Closely)

  • Cytotoxic chemotherapy: may increase hematologic toxicity.
  • Targeted therapies (e.g., tyrosine kinase inhibitors): potential overlapping adverse effects.
  • Anticoagulants: monitor for bleeding if immune‑related thrombocytopenia occurs.

Frequently Asked Questions

Opdivo (nivolumab) is approved for several advanced malignancies, including melanoma, non‑small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and microsatellite instability‑high colorectal cancer. It works by enhancing the immune system’s ability to recognize and destroy tumor cells.

Nivolumab is a monoclonal antibody that blocks the programmed death‑1 (PD‑1) receptor on T cells. By preventing PD‑1 from binding its ligands PD‑L1 and PD‑L2, the drug lifts the inhibitory signal that normally dampens immune activity, allowing T cells to remain active and attack cancer cells more effectively.

The dosing regimen for Opdivo is individualized by the prescribing oncologist based on the specific indication, patient weight, and clinical factors. Healthcare providers determine the appropriate dose, infusion schedule, and any necessary adjustments.

Safety data for Opdivo in pregnant or breastfeeding individuals are limited. The drug may cross the placenta and is excreted in breast milk, so it is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the Opdivo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Opdivo (nivolumab) targets the PD‑1 receptor, similar to pembrolizumab, but differences exist in dosing schedules, approved indications, and clinical trial outcomes. Both agents enhance T‑cell activity, yet individual patient factors and tumor characteristics guide the choice of one over the other.

Opdivo must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Opdivo is given by subcutaneous injection under the supervision of a qualified healthcare professional. The infusion is typically performed in a clinical setting, and patients are monitored for any immediate infusion‑related reactions.

Serious risks include immune‑mediated adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and severe infusion reactions. Early detection and prompt management are essential, and patients should be educated to report symptoms like persistent cough, severe diarrhea, jaundice, or unexplained fatigue.

Opdivo is contraindicated in patients with known hypersensitivity to nivolumab or any of its excipients. It should also be avoided in individuals receiving live vaccines, those with uncontrolled active infections, and organ transplant recipients due to the risk of graft rejection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nivolumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT